{
    "clinical_study": {
        "@rank": "77174", 
        "acronym": "PGA", 
        "arm_group": [
            {
                "arm_group_label": "Poly-gamma Glutamic Acid", 
                "arm_group_type": "Experimental", 
                "description": "Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered  Poly-gamma Glutamic Acid for 4 weeks."
            }, 
            {
                "arm_group_label": "Maltose", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients with cervical intraepithelial neoplasia 1(CIN1) will be administered  placebo for 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the efficacy and the safety of PGA(Poly-gamma\n      Glutamic Acid) for the the fertile women with Cervical Intraepithelial Neoplasia (CIN1)."
        }, 
        "brief_title": "Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Cervical Intraepithelial Neoplasia", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Cervical Intraepithelial Neoplasia", 
                "Carcinoma in Situ"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is to compare the regression rate of Cervical Intraepithelial Neoplasia (CIN1)\n      between the treatment group and the control group.\n\n      The treatment group will be administered with PGA (Poly-gamma Glutamic Acid) for 4 weeks\n      followed by 8 weeks observation.\n\n      The control group will be observed for 12 weeks without any comparator."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Fertile women between age of 20 and 40\n\n          -  Patients with cervical intraepithelial neoplasia 1(CIN1)\n\n          -  HPV(Human Papilloma Virus) positive(+)\n\n          -  White Blood Cell Count(WBC) over 4thous/ul, Hemoglobin above over 9.0g/dL Platelet\n             over 150thous/uL and ANC(Absolute Neutrophil Count) over 1,500 10^6/L\n\n          -  AST(Aspartate Aminotransferase) no less than 4 times higher than normal ALT(Alanine\n             Aminotransferase) no less than 4 times higher than normal\n\n          -  Normal for EKG(Electrocardiography) and no active disease detected trough chest X-ray\n\n          -  Be informed of the nature of the study and will give written informed consent\n\n        Exclusion Criteria:\n\n          -  Malignant tumor in any organ other than cervical intraepithelial neoplasia\n\n          -  Active liver disease, immune disorder and severe renal failure\n\n          -  Leukemia, collagenosis, sclerosis, autoimmune disease, clinically significant\n             allergic disease(mild allergic symptom not required medicine excluded)\n\n          -  Diagnosed diabetes\n\n          -  Taking any of followings affecting immunological reaction within 7 days\n             (Glucocorticoid, vitamins, health food and oriental medicine etc)\n\n          -  Pregnancy and breastfeeding\n\n          -  Registered in other clinical trials\n\n          -  Patients whom the investigator considers inappropriate to participate in the study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "49 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01826045", 
            "org_study_id": "UMT2012-BL-PGA-01", 
            "secondary_id": "12335"
        }, 
        "intervention": [
            {
                "arm_group_label": "Poly-gamma Glutamic Acid", 
                "intervention_name": "Poly-gamma Glutamic Acid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Maltose", 
                "intervention_name": "maltose", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Treatment of Cervical Intraepithelial Neoplasia(CIN1)", 
        "lastchanged_date": "January 13, 2014", 
        "location": {
            "contact": {
                "email": "jklee38@korea.ac.kr", 
                "last_name": "Jae_Kwan Lee, MD, PhD", 
                "phone": "+82-2-2626-3142"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "152-703"
                }, 
                "name": "Korea University Guro Hospital"
            }, 
            "investigator": {
                "last_name": "Jae-Kwan Lee, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-center, Randomized, Double Blind, Placebo Control, Parallel Design, Phase 2a Trial to Evaluate the Efficacy and Safety of PGA (Poly-gamma Glutamic Acid) for the Fertile Women With Cervical Intraepithelial Neoplasia 1 (CIN1)", 
        "other_outcome": [
            {
                "description": "Adverse events will be monitored for 12 weeks.", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "Vital signs will be monitored for 12 weeks.", 
                "measure": "Vital Signs", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "Result of laboratory tests will be assessed at screening.", 
                "measure": "Laboratory Tests", 
                "safety_issue": "Yes", 
                "time_frame": "up to 12 weeks"
            }
        ], 
        "overall_contact": {
            "email": "jspark@catholic.ac.kr", 
            "last_name": "Jong Sup Park, MD, PhD", 
            "phone": "+82-2-2258-6168"
        }, 
        "overall_official": [
            {
                "affiliation": "Korea University Guro Hospital", 
                "last_name": "Jae-Kwan Lee, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kwandong University College of Medicine Cheil Hospital", 
                "last_name": "Tae Jin Kim, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Catholic University, Korea Seoul St Mary's Hospital", 
                "last_name": "Jong Sup Park, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Regression rate will be assessed at the time of screening and 12 weeks. Regression means the change from the stage of CIN1 to normal.", 
            "measure": "Regression rate", 
            "safety_issue": "No", 
            "time_frame": "up to 12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01826045"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Reid Colposcopic Index will be assessed at the time of screening and 12 weeks.", 
                "measure": "Reid Colposcopic Index", 
                "safety_issue": "No", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "Result of Pap smear test will be assessed at the time of screening and 12 weeks.", 
                "measure": "Pap smear test", 
                "safety_issue": "No", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "Result of HPV (Human Papilloma Virus) DNA Test will be assessed at the time of screening and 12 weeks.", 
                "measure": "HPV (Human Papilloma Virus) DNA Test", 
                "safety_issue": "No", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "Result of HPV (Human Papilloma Virus) Hybrid CaptureII Test will be assessed at the time of screening and 12 weeks.", 
                "measure": "HPV (Human Papilloma Virus) Hybrid CaptureII Test", 
                "safety_issue": "No", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "Result of NK (Natural Killer) Cell Activity will be assessed at the time of baseline (0day), 4 weeks, 8 weeks and 12 weeks.", 
                "measure": "NK (Natural Killer) Cell Activity", 
                "safety_issue": "No", 
                "time_frame": "up to 12 weeks"
            }, 
            {
                "description": "Result of Peripheral Blood Mononuclear Cells (PBMCs) Test will be assessed at the time of baseline (0day), 4 weeks, 8 weeks and 12 weeks.", 
                "measure": "Peripheral Blood Mononuclear Cells (PBMCs)Test", 
                "safety_issue": "No", 
                "time_frame": "up to 12 weeks"
            }
        ], 
        "source": "BioLeaders Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioLeaders Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}